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Abstract
The Centers for Disease Control and Prevention’s (CDC) Division of STD Prevention, in 
collaboration with the Association of Public Health Laboratories (APHL), is developing a 
nationally available syphilis serum repository for research of Food and Drug Administration 
(FDA)-cleared or investigational syphilis diagnostic assays in the United States. State and local 
public health laboratories (PHL) submitted de-identified residual sera with information on 
collection date, volume, storage conditions, freeze-thaw cycles, PHL serology results, reported 
syphilis stage and demographic details if available. Previous test results were blinded and sera 
(N=152 reported syphilis stage, N = 131 unknown status) were tested at CDC using five FDA-
cleared and one investigational syphilis tests. Treponemal and nontreponemal test sensitivity 
ranged from 76.3–100% and 63.2–100%, respectively, among staged specimens. The conventional 
treponemal assays showed high concordance of 95.4%. By providing syphilis stage and 
comprehensive serological test data, developed repository may serve as a valuable resource for 
diagnostic test validation studies.
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1. Introduction
Treponema pallidum subspecies pallidum is the etiological agent of syphilis and is 
transmitted sexually, vertically from an infected mother to her child, and rarely by blood 
transfusion or other nonsexual contact (Goh, 2005). Untreated syphilis progresses through 
primary, secondary, early/late latent, and tertiary disease stages. Recent national surveillance 
reports from the Centers for Disease Control and Prevention (CDC) have shown primary and 
secondary syphilis as being on the rise in the United States (US) (Workowski and Bolan, 
2015). A total of 30,644 primary and secondary syphilis cases were reported in 2017, with 
men who have sex with men (MSM) accounting for the majority of cases (Centers for 
Disease Control and Prevention, 2017b). An increase in the rate of congenital syphilis has 
also been reported, with 918 congenital syphilis cases being recorded (including 64 still 
births, and 13 infant deaths) in 2017 at a national rate of 23.3 cases per 100,000 live births. 
These data indicate a 43.8% increase from 2016 (16.2 cases per 100,000 live births) and a 
153.3% increase from 2013 (9.2 cases per 100,000 live births) (Centers for Disease Control 
and Prevention, 2017b).
The diagnosis of syphilis involves serological techniques and direct detection methods, 
along with patient history and clinical symptoms (Henao-Martinez and Johnson, 2014; 
Morshed and Singh, 2015; Ratnam, 2005). The use of direct detection techniques is however 
often limited to research or field settings, with diagnostic laboratories primarily using 
serological tests that include nontreponemal and treponemal categories. Nontreponemal 
antibodies are produced during active syphilis in response to the lipoidal moieties released 
from damaged host cells and possibly also from the treponemes during infection (Jost et al., 
2013; Larsen and Johnson, 1998; Morshed and Singh, 2015). Venereal Disease Research 
Laboratory (VDRL), Rapid Plasma Reagin (RPR), Unheated Serum Reagin (USR) and 
Toluidine Red Unheated Serum Test (TRUST) are examples of the nontreponemal syphilis 
tests that are capable of detecting immunoglobulin (Ig) G and IgM classes of antibody to 
cardiolipin, lecithin, and cholesterol in serum or plasma (Larsen et al., 1995). However, false 
reactive nontreponemal tests may be associated with hepatitis, viral infections, malaria, 
leprosy, intravenous drug use, pregnancy or linked to connective tissue diseases such as 
systemic lupus erythematous (Binnicker et al., 2011; Larsen et al., 1995; Morshed and 
Singh, 2015). It is therefore recommended that a reactive nontreponemal result be followed 
by a treponemal test that typically includes whole bacteria or highly purified treponemal 
peptides/proteins as target antigen(s) in the assay design. Treponemal tests detect antibodies 
specific for T. pallidum antigen (s) which result from active or previously treated T. pallidum 
infection. T. pallidum Particle Agglutination (TP-PA), T. pallidum Hemagglutination Assay 
(TPHA), Fluorescent Treponemal Antibody-Absorption (FTA-ABS), Trep-Sure Enzyme 
Immunoassay (EIA), INNO-LIA Syphilis Score (Line Immunoassay, LIA), automated 
LIAISON treponema assay (Chemiluminescence Immunoassay, CIA) are examples of 
treponemal tests. Recently, the Food and Drug Administration (FDA) cleared the use of a 
rapid immunochromatographic test, Syphilis Health Check (Rapid Syphilis Test, RST), for 
T. pallidum specific antibody detection (Matthias et al., 2016; Pereira et al., 2018). This test 
is also CLIA-waived (Clinical Laboratory Improvement Amendments) and can easily be 
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performed by a trained non-laboratorian, while being cognizant of quality control, 
competency, training, and proficiency testing.
Although many syphilis serological assays are commercially available, deciding which to 
use as a screening or confirmatory test can be challenging for a laboratory due to factors 
such as testing volume and frequency, turnaround time, accuracy and cost involved. The 
serological diagnosis of syphilis follows one of two testing algorithms in the US. The 
traditional algorithm begins with a nontreponemal test as a screening test, and if reactive, 
followed by a treponemal test as mentioned above (Loeffelholz and Binnicker, 2012). This 
practice is still in use as a standard algorithm in many laboratories for syphilis screening. 
Conversely, the reverse algorithm utilizes a treponemal test (EIA/CIA, automated) for initial 
screening, and if reactive, is followed by a nontreponemal test (Loeffelholz and Binnicker, 
2012). To manage discordant test results (e.g. treponemal reactive and non-treponemal non-
reactive), reflex testing with another treponemal test, TP-PA, is recommended (Centers for 
Disease and Prevention, 2011; Park et al., 2019). The reverse algorithm is increasingly being 
applied due to the high throughput and improved work flow associated with automated 
treponemal tests, and it also potentially has higher sensitivity for primary and latent stage 
syphilis detection compared to nontreponemal tests (Donkers et al., 2014).
To support the field’s advancement of syphilis diagnostic tests in the US, CDC and the 
Association of Public Health Laboratories (APHL) collaborated to collect, characterize, and 
provide syphilis specimens as a resource for research, public health, clinical or commercial 
institutions that perform syphilis test validation and/or development. This work aligns with a 
goal highlighted in 2016 CDC syphilis summit (Kersh and Lukehart, 2018) and the 2017 
National Call to Action (Centers for Disease Control and Prevention, 2017a) that envisioned 
development of a characterized specimen repository. Described herein are the methods used 
to acquire and test submitted specimens, using syphilis serological tests to comprehensively 
characterize the panels for the repository. The nontreponemal RPR test and the treponemal 
TP-PA, EIA, LIA, and CIA were selected for specimen testing based on the routine 
application of these assays in syphilis test algorithms and the availability of previously 
reported performance data (Hagedorn et al., 2002; Jost et al., 2013; Larsen and Johnson, 
1998; Zhang et al., 2012). Since these tests are all conventional laboratory assays, Syphilis 
Health Check, was also included to obtain RST data for these specimens and to shed light on 
its performance as a treponemal assay in relation to syphilis disease stage, given that it is a 
relatively new test in the field of syphilis diagnostics.
2. Materials and methods
2.1. Specimens
Association of Public Health Laboratories (APHL) members from 11 state and/or local 
public health laboratories provided 464 human serum samples to the CDC through a joint 
collaborative effort. Approvals in accordance with federal regulations, state laws, ethics 
guidelines, and CDC regulatory policies were obtained prior to specimen collection and 
CDC laboratory testing. These sera were collected by the PHL from years 2012–2016 in 
response to a solicitation by the APHL to its membership, and are intended to facilitate 
serological test validation and development in the syphilis field, with specimen panels 
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prepared, banked and provided by the CDC. Contributing laboratories submitted 
anonymized specimens that were unlinked from personally identifying information (PII) and 
were assigned an APHL study number, with an additional de-linking step performed at the 
CDC. Limited information was provided with each specimen and included state of origin, 
with the source being either a state or local public health laboratory, and non-identifying 
data such as age, sex, reported syphilis stage (when available from the test request form or as 
reported by the program following CDC case definitions), diagnostic test utilized, and 
previous test results (Table 1). Of the 464 specimens provided to the CDC, 283 met the 
minimum 2 mL sample volume requirement that would be sufficient for both downstream 
assays and archiving. The specimens were further divided based on the inclusion of syphilis 
status where 152 specimens had reported syphilis disease stage, 109 reported as being 
unknown for syphilis stage, and 22 being reported as serofast status. Out of 464 specimens, 
183 had insufficient specimen volume (< 2 ml) and were excluded for this study, but were 
archived for internal quality control studies at the CDC. All specimens were shipped frozen 
on dry ice and stored at −80 °C until tested. Only one freeze thaw cycle was reported by the 
submitters.
2.2. Serological assays
The diagnosis of syphilis is dependent on the use of nontreponemal and treponemal tests, 
hence both test types were included in our evaluation. The 283 specimens that met the 
minimum volume requirement were tested with nontreponemal RPR (ASI RPR card test, 
Arlington Scientific, UT, USA), and treponemal-TP-PA (Serodia TP-PA, Fujirebio, Japan), 
EIA (Trep-Sure EIA, Trinity Biotech, NY, USA), LIA (INNO-LIA syphilis score, Fujirebio, 
Japan), an automated CIA (LIAISON treponema assay, DiaSorin, Italy), and RST (Syphilis 
Health Check, Trinity Biotech NY, USA). CDC laboratorians performing the serological 
tests were initially blinded to the previously reported test results and reported syphilis stage 
or status that were provided by the APHL member public health laboratories. All testing and 
result interpretations were performed according to respective manufacturer’s directions. 
After completion of tests, residual specimens were prepared as 0.2 ml aliquots and archived 
for repository purposes.
2.3. Data analysis
Diagnostic sensitivity of the evaluated tests using PHL-reported syphilis staged specimens 
(primary, secondary, early latent, late latent and unclassified latent) were calculated using 
standard formula as follows (Larsen and Johnson, 1998):
%Sensitivity =[True positive/(True positive + False negative)] × 100
Where, true positive represents syphilis staged specimens found reactive by a given test, and 
false negative is staged specimens nonreactive by that same test.
A comparative analysis was performed among four conventional laboratory serological 
assays. Results of three treponemal tests EIA, CIA and TP-PA were analyzed to get 
percentage concordance/discordance in the context of syphilis staged specimens. RPR 
results simultaneously obtained were compared to treponemal data. The RST and LIA were 
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excluded for this analysis due to their relatively new and/or investigational status, and most 
PHL settings use conventional laboratory serological assays for specimen testing.
3. Results
3.1. Repository content and accessibility
A summary of data for all specimens received thus far from the APHL member public health 
laboratories are shown in Table 1, which indicate specimen source, clinical information and 
patient demographics. Concurrent with specimen accrual and characterization, a public 
website, https://www.cdc.gov/std/syphilis/lab/serumbank.htm, was developed by the CDC to 
provide general information about the repository and the process to request specimens, 
which involves submission of a brief proposal via the website. Upon approval, a contract of 
agreement and detailed inventory of specimen panels along with CDC-characterized test 
results will be provided to the requestor for selection and procurement of a limited number 
of specimens per annum.
3.2. Repository characterization
Since diagnostic testing was performed by multiple laboratories across the US, there was 
variability in the type of test and/or algorithm applied, with a given laboratory using any one 
or combination of RPR, VDRL or USR for nontreponemal testing, and/or TP-PA, EIA, FTA-
ABS or Captia syphilis G for treponemal testing. Test results and clinical status information 
for the specimens were reported by the PHL and are documented as is by our laboratory at 
the CDC. Thus, in order to better characterize and provide a degree of standardization across 
specimens, comprehensive testing was performed at our laboratory using five FDA-cleared 
and one investigational serological assay. For the 152 specimens that included reported 
syphilis stage information, testing using the six serological assays showed overall 
sensitivities ranging from 85–98% as shown in Table 2. The nontreponemal RPR yielded 
sensitivity of >90% for primary, secondary, early latent, and unclassified latent staged 
specimens and showed sensitivity of 63.2% for the late latent specimens. Treponemal assays 
(TP-PA, EIA, LIA and CIA) showed sensitivities in the range of 90–100% across all 
reported stages of syphilis. The RST, Syphilis Health Check, showed sensitivity in the range 
of 76–96%. Testing of 131 unstaged syphilis specimens had yielded sensitivity of 70–100% 
among which specimens with serofast status (n=22) had a sensitivity of 100% for both RPR 
and TP-PA, and of 95.4% for EIA, LIA, and CIA. With the same specimens, RST showed a 
sensitivity of 90.9% (Table 2). Out of 22 serofast specimens, 18 had RPR titers ≤1:8 or less 
(data not shown). Testing of specimens categorized as unknown under unstaged syphilis 
showed a sensitivity of >90% for TP-PA, EIA, LIA, and CIA, while being 70.6% and 78.9% 
for RPR and RST respectively (Table 2).
Table 3 shows comparative analysis of four conventional FDA-cleared syphilis serology 
laboratory tests in the context of disease stage. Among the three conventional treponemal 
tests, a concordance of 95.4% was noted. Four specimens had discordant treponemal results 
(2.6%), with two of the three treponemal tests showing either reactive or nonreactive results 
for a given specimen. One unclassified latent staged specimen (0.6%) showed nonreactive 
results by all three treponemal tests, but was reactive by RPR (minimal reactivity, Rm), 
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while 16 specimens (10.5%) across all stages showed the opposite outcome. Three late latent 
staged specimens (2.0%) yielded indeterminate results with CIA and/or TP-PA and were 
excluded for this analysis. All four conventional assays showed reactive results with 84.2% 
of specimens tested.
4. Discussion
A national syphilis serum repository has been developed at the CDC consisting of staged 
and unstaged (serofast or unknown status) syphilis specimens with comprehensive 
laboratory-characterized serological test data. The repository is intended to support research, 
public health, clinical or commercial institutions that develop and/or validate novel and 
existing syphilis diagnostic assays for use and/or FDA clearance in the US. Since the 
repository may be used not only to develop novel syphilis assays, but also to evaluate the 
performance of new tests relative to existing assays, the characterization of sera for the 
repository was not limited to determining reactivity status alone; performance data for an 
array of currently available tests was also assessed to provide a frame of reference for 
laboratories that may conduct similar assays using specimens from this repository. 
Importantly, the performance data described in this study lends credence to the quality of the 
repository specimens, as the overall level of sensitivity yielded for nontreponemal RPR and 
treponemal tests including RST are consistent with previous studies (Castro et al., 2003; 
Hagedorn et al., 2002; Pereira et al., 2018; Sena et al., 2010).
The repository development initiative provided a unique research opportunity to evaluate test 
results in the context of reported syphilis stage. The investigational treponemal LIA showed 
sensitivity comparable to the standard treponemal assays for staged specimens, while the 
EIA showed the highest sensitivity among the other tests considered in this study. However, 
there was generally high concordance among the treponemal assays tested, which is 
consistent with prior findings (Jost et al., 2013; Larsen and Johnson, 1998). The data 
obtained also reiterates the higher sensitivity of treponemal tests for detecting antibodies in 
syphilis specimens from all stages (Park et al., 2019). However, discordant and inconclusive 
results were noted among the treponemal tests that were evaluated, mainly with primary, 
early latent, and late latent staged specimens. The intrinsic differences in treponemal assay 
design or platform could contribute to the observed discrepancies as the analytical sensitivity 
varies among tests (Jost et al., 2013). Of note, one unclassified latent staged specimen 
showed nonreactive treponemal results but a minimal reactive result in RPR, suggesting a 
false positive case (Ratnam, 2005), though additional clinical history related to the specimen 
would be needed to guide further interpretation of these findings.
The discrepancies observed between treponemal results and those obtained by RPR testing 
suggest a lower sensitivity of RPR for the staged specimens tested in this study (Table 2). 
The sensitivity of RPR is reduced during early or late syphilis (Larsen and Johnson, 1998). 
In addition, prior successful treatment for syphilis could account for diminished RPR 
sensitivity or reversion to nonreactive status (Larsen and Johnson, 1998; Ratnam, 2005). In 
the case of secondary staged specimens that yielded nonreactive RPR and reactive 
treponemal test results, the prozone effect was considered due to the presence of high levels 
of antibodies during this stage of infection (Morshed and Singh, 2015). However, this 
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possibility was excluded by semi-quantitative RPR testing for all four RPR nonreactive-
secondary staged specimens. In addition to parameters discussed above, the presence of 
concomitant sexually transmitted infections such as HIV and the potential impact of co-
infections on the outcome of various test types cannot be ruled out (Larsen et al., 1995; 
Morshed and Singh, 2015). However, our laboratory is not privy to information on prior or 
current treatment history, co-infections, or other disease conditions linked to this specimen 
set. It is also important to note that the current study’s evaluation is based on the syphilis 
stage reported by the PHL that provided the specimens, and these diagnoses could not be 
independently verified by us. Furthermore, frozen specimens were used for analysis when 
most assay manufacturers recommend use of fresh specimens. However, freeze-thaw cycles 
were kept to a minimum and a previous CDC study has shown that as many as ten freeze-
thaw cycles have negligible impact on treponemal antibody reactivity when using EIA 
(Castro and Jost, 2013).
In summary, we demonstrated methods used for development of a syphilis serum repository 
through a collaborative initiative with APHL. The performance data of syphilis tests 
described herein will broaden insight on assay’s sensitivity in the context of syphilis stage. 
Indeed, there are limited number of studies that validate syphilis test performance – 
nontreponemal or treponemal-in relation to disease stage and this work may contribute new 
data in that respect. Our study is not intended to alter previously issued recommendations for 
a sequence algorithm(s) of laboratory-based serological tests to confirm ambiguous results. 
Indeed, these data collectively underscore the need to confirm or verify results with an 
additional test type(s), as recommended by current algorithms that are used to guide syphilis 
diagnosis. Factors that include clinical history and geographical prevalence should also be 
taken into consideration for syphilis diagnosis (APHL, 2015; Binnicker et al., 2012; Centers 
for Disease and Prevention, 2011; Park et al., 2019). Efforts to expand the CDC serum 
repository in collaboration with APHL member public health laboratories are ongoing.
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